Jiangsu Hengrui Pharmaceuticals announced that the company has reached an agreement with IDEAYA Biosciences to grant a paid license for the independently developed Class 1 new drug injectable SHR-4849 to IDEAYA Biosciences. IDEAYA Biosciences will gain exclusive rights to develop, produce, and commercialize SHR-4849 globally outside of Greater China. IDEAYA Biosciences will pay Jiangsu Hengrui a signing fee of 75 million USD and will pay cumulative R&D milestone payments of up to 0.2 billion USD and cumulative sales milestone payments of up to 0.77 billion USD based on the development and approval status of SHR-4849 globally outside Greater China, as well as actual annual net sales. IDEAYA Biosciences will also pay Jiangsu Hengrui a sales commission based on a percentage between one to two digits of the actual annual net sales.
恒瑞医药：与IDEAYA Biosciences签署SHR-4849项目授权许可协议
Jiangsu Hengrui Pharmaceuticals: Signed a licensing agreement for the SHR-4849 project with IDEAYA Biosciences.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated